PhaseBio Pharmaceuticals Operating Cash Flow

Operating Cash Flow of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending September 29, 2021 was $-6.13 Million (a -44.71% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow decreased by -45.95%
  • Annual Operating Cash Flow for 2020 was $-60 Million (a 51.43% increase from previous year)
  • Annual Operating Cash Flow for 2019 was $-39.6 Million (a 132.18% increase from previous year)
  • Annual Operating Cash Flow for 2018 was $-17.1 Million (a 106.48% increase from previous year)
  • Twelve month Operating Cash Flow ending September 29, 2021 was $-38.8 Million (a -20.01% decrease compared to previous quarter)
  • Twelve month trailing Operating Cash Flow decreased by -35.34% year-over-year
Trailing Operating Cash Flow for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-38.8 Million $-48.5 Million $-46.3 Million $-60 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of PhaseBio Pharmaceuticals

Most recent Operating Cash Flowof PHAS including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-6.13 $-11.09 $-10.2
2020 $-11.35 $-15.83 $-8.96 $-23.83 $-59.96
2019 $-12.49 $-8.24 $-10.13 $-8.73 $-39.59
2018 $-6.84 $-3.58 $-4.01 $-2.63 $-17.05
2017 $-2.42 $-5.84 $-8.26
2016 $-9.69

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.